« Back

GTx, Inc. Announces Financial Release, Conference Call and Webcast

Feb 25, 2004 at 12:00 AM EST
Contact:
GTx, Inc.
Carney Duntsch
Investor and Media Relations
901-523-9700 ext. 170
cduntsch@gtxinc.com
 

Burns McClellan, Inc.
Jonathan M. Nugent (investors)
Kathy L. Jones-Nugent, Ph.D. (media)
212-213-0006







GTx, Inc. Announces Financial Release, Conference Call and Webcast

MEMPHIS, Tenn., Feb. 25 /PRNewswire-FirstCall/ -- GTx, Inc. (Nasdaq: GTXI), a biopharmaceutical company dedicated to the development and commercialization of therapeutic products for men's health, today announced that Mitchell Steiner, M.D., Vice Chairman and CEO, will host a conference call and webcast to discuss 2003 fourth quarter and year-end financial results and provide an update on corporate and clinical progress on Wednesday, March 3, 2004 at 10:00 a.m., Eastern Time. The call and webcast will follow the release of 2003 fourth quarter and year-end financial results earlier that day.

To listen to the conference call, please dial 800-915-4836 from the United States or Canada or 973-317-5319 from outside North America. A playback of the call will be available starting at 12:00 p.m. Eastern Time March 3, 2004 through March 10, 2004 and may be accessed by dialing 800-428-6051 from the United States or Canada or 973-709-2089 from outside North America, and referencing reservation number 340140. Additionally, you may access the live and subsequently archived webcast of the conference call from the Investor Relations section of our website at www.gtxinc.com.

About GTx
GTx is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men's health conditions. GTx's drug discovery and development programs are focused on small molecules that selectively modulate the effects of estrogens and androgens. GTx currently has two product candidates that are in human clinical trials. The company is developing Acapodene, its most advanced product candidate, through clinical trials for two separate indications: (1) a Phase IIb clinical trial for the reduction in the incidence of prostate cancer in men with precancerous prostate lesions and (2) the pivotal Phase III clinical trial for the treatment of serious side effects of advanced prostate cancer therapy. GTx is initially developing its second product candidate, Andarine, for the treatment of muscle wasting weight loss, or cachexia, that occurs from various types of cancer.

SOURCE GTx, Inc. 02/25/2004 /CONTACT: Amy Bethea, Manager Corporate Communications of GTx, Inc., +1-901-523-9700, ext., 108; or E. Blair Schoeb (Investors), or Trica Morsch (Public Relations), both of Burns McClellan, +1-212-213-0006, for GTx, Inc. / /First Call Analyst: / /FCMN Contact: abethea@gtxinc.com / /Web site: http://www.gtxinc.com / (GTXI)